Connect with us

Health

Lower-income EU countries are paying more for cancer medicines

SHARE:

Published

4 months ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

A European Fair Pricing Network study reveals that lower-income countries are paying more for their medicines.

A study, entitled “Price transparency of cancer medicines: a crucial step towards informed pricing negotiations in the European region”, involving 23 hospitals from nine European countries, reveals significant price variations for 15 cancer medicines both between and within countries. In some instances, hospitals are paying much more for the exact same medicine.

The European Cancer League, one of the network’s members, wrote: “Many hospitals across Europe are unknowingly paying far more than others. For example, hospitals in Hungary pay almost three times more than those in Germany for medication used to treat breast, colorectal, and gastric cancers.”

Guy Muller, who works with the Dutch Cancer Society, says the study challenges the widespread assumption that cancer drugs are always priced higher in countries with stronger economies: “In fact, countries with lower spending power often face higher hospital prices for cancer medicines. In...

Share this article:

Share this:
Related Topics:
Guest Contributor - Opinion

Opinions expressed are purely those of the author and not endorsed by EU Reporter. The article was unsolicited by EU Reporter, and the author guarantees the truthfulness of the contents of the article. No payment was made by EU Reporter to the author

EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending